BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dicerna Pharmaceuticals 

480 Arsenal Street
Building 1, Suite 120
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-621-8097 Fax: n/a


SEARCH JOBS





Segment
Start Up





 Company News
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna (DRNA)’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 4/23/2015 8:21:58 PM
Dicerna (DRNA) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 4/1/2015 3:34:17 PM
Dicerna (DRNA) Announces Fourth Quarter And Full Year 2014 Financial And Operational Results 3/13/2015 9:50:55 AM
Dicerna (DRNA) To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On March 12, 2015 3/10/2015 11:12:05 AM
Booming Dicerna (DRNA) Takes a Larger Space in Cambridge and Plans to Hire 2/26/2015 6:06:14 AM
Dicerna Pharmaceuticals (DRNA) To Present At The 2015 Leerink Global Healthcare Conference 2/5/2015 11:19:16 AM
Dicerna Pharmaceuticals (DRNA) Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of DCR-MYC, An Investigational Rnai Therapeutic Targeting The MYC Oncogene, In Patients With Advanced Hepatocellular Carcinoma 2/2/2015 10:44:45 AM
Dicerna Pharmaceuticals (DRNA) Presents Positive Preclinical Data On Its DsiRNA Therapeutics Targeting MYC And ?-Catenin At American Association for Cancer Research MYC: From Biology To Therapy Meeting 1/12/2015 12:53:51 PM
Dicerna Pharmaceuticals (DRNA) Announces Issuance Of US Patent Providing Broad Coverage Of DsiRNA-EX RNAi Payloads 1/12/2015 12:47:47 PM
Dicerna Pharmaceuticals (DRNA) Announces The Appointment Of Theodore T. Ashburn, M.D., Ph.D. To Senior Vice President, Product Strategy And Operations, And Inducement Grant Of Stock Options Under NASDAQ Listing Rule 5635 (C)(4) 12/18/2014 9:23:33 AM
12345678910